Results 1 to 10 of about 13,819 (183)

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Bioactives From Brown Algae: Antioxidant, Anti‐Inflammatory, Anticancer, and Antimicrobial Potential

ChemBioEng Reviews, EarlyView.
This review explores key bioactives in brown algae and their antioxidant, anti‐inflammatory, anticancer, and antimicrobial properties. Covering studies from 2014 to 2024, it highlights their relevance in pharmaceuticals, nutraceuticals, cosmetics, and foods, while addressing challenges and future directions to unlock their full potential.
Irvin Fonseca‐Barahona, Kaveh Shahbaz, Saeid Baroutian   +2 more
wiley   +1 more source

Evaluation of the Antifungal Properties of Azomethine‐Pyrazole Derivatives from a Structural Perspective

ChemistryOpen, EarlyView.
A series of azomethine‐pyrazole derivatives bearing a para‐substituted azo‐phenyl ring is straightforwardly prepared. The new compounds display an elevated antifungal activity against various Candida species and Cryptococcus neoformans strains. DFT and molecular docking calculations are used to determine possible routes of action through interactions ...
María Isabel Murillo, Andrés Camilo Restrepo‐Acevedo, Cristian Rocha‐Roa, Susana Zacchino, Laura Svetaz, Simón Hernández‐Ortega, Rodrigo Abonia, Ronan Le Lagadec, Fernando Cuenú‐Cabezas   +8 more
wiley   +1 more source

Long‐term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium

British Journal of Haematology, EarlyView.
The overall survival of patients receiving an allogeneic haematopoietic stem cell transplant (HSCT) for GATA2 deficiency was significantly better if they were transplanted recently, with a bone marrow or cord blood graft and if the transplant was performed before the onset of excess blast. Excess blast before HSCT was the only factor associated with an
Flore Sicre de Fontbrune, Florian Chevillon, Mony Fahd, Kristell Desseaux, Xavier Poiré, Edouard Forcade, Arthur Sterin, Bénédicte Neven, Virginie Gandemer, Sylvain Thepot, Alice Garnier, Bruno Lioure, Ambroise Marcais, Stephanie Nguyen‐Quoc, Suzanne Tavitian, Laure Vincent, Jean Donadieu, Matthieu Resche Riggon, Sylvie Chevret, Marlene Pasquet, Regis Peffault de Latour   +20 more
wiley   +1 more source

Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach

Internal Medicine Journal, Volume 55, Issue 5, Page 749-759, May 2025.
Abstract Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach to AML induction with 7+3 chemotherapy (7 days of infusional cytarabine with three doses of anthracycline ...
Aditya Tedjaseputra, Amanda Tey, Anastasios Nalpantidis, George Grigoriadis, Shaun Fleming, Shahla Vilcassim, Pasquale L. Fedele, Michael Sze Yuan Low, Paul Yeh, Michael Gilbertson, Ashwini Bennett, Gareth P. Gregory, Danielle Oh, Donna Gairns, Zane Kaplan, Sanjeev D. Chunilal, Susan Brown, Stephen Opat, Chong C. Chua, Jake Shortt   +19 more
wiley   +1 more source

Filling the gaps to empower regional centres to manage myelodysplastic syndrome and acute myeloid leukaemia leading to wider cancer healthcare delivery and access to clinical trials

Internal Medicine Journal, Volume 55, Issue 5, Page 722-727, May 2025.
Abstract Background The management of patients with haematological malignancies in rural and regional Australia is different to that in metropolitan centres due to many factors. Lower‐intensity and easier‐to‐access treatments that are now available for acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) have improved the deliverability of ...
Michael Ashby, Shaun Fleming, Andrew Spencer, Anne Woollett, Tricia Wright   +4 more
wiley   +1 more source

Fungal dysbiosis following antibacterial monotherapy in canine otitis externa

Journal of Small Animal Practice, Volume 66, Issue 3, Page 149-157, March 2025.
Objectives To evaluate evidence of Malassezia overgrowth following successful topical antibacterial monotherapy of refractory canine bacterial otitis using semi‐quantitative cultures. Materials and Methods Twenty‐nine dogs with bacterial otitis were treated topically with either fluoro‐quinolone [0.5% enrofloxacin (18 dogs, 19 treatment events, 25 ears)
J. Juhola, E. Brennan, E. A. Ferguson, A. Loeffler, A. Hendricks, S. M. Frosini, Y. M. Chang, R. Bond   +7 more
wiley   +1 more source

Single‐Dose, Intravenous, and Oral Pharmacokinetics of Isavuconazole in Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Isavuconazole, a triazole antifungal used in humans for invasive fungal infections, may be effective for treating canine fungal infections, although data on its use in dogs is limited. This study aimed to determine the pharmacokinetics and safety of a single dose of isavuconazole in dogs, administered both intravenously and orally. Six healthy
Yishan Kuo, Zhong Li, Lauren E. Forsythe, Jennifer M. Reinhart   +3 more
wiley   +1 more source

Infections Management in the Lung Transplant Setting in Italy: A Web‐Survey

Transplant Infectious Disease, Volume 27, Issue 2, March/April 2025.
A web survey has revealed significant variation in infection management practices across Italian lung transplant centers. These differences encompass key aspects of infection prevention and control, including antibiotic protocols and cytomegalovirus prophylaxis, underscoring a lack of consistency in fundamental strategies.
Andrea Lombardi, Paolo Grossi, Malgorzata Mikulska, Maddalena Giannella, Renato Pascale, Serena Marinello, Francesca Montagnani, Elena Seminari, Silvia Corcione, Alessandra Bandera, Alessandro Bertani, Alessandra Mularoni, for the Infection Prevention and Treatment Working Group of the LUNG‐SITO study group   +12 more
wiley   +1 more source

Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)

Cancer Innovation, Volume 4, Issue 3, June 2025.
ABSTRACT Background The phosphoinositide 3‐kinase (PI3K)/protein kinase B (PKB or AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays a critical role in breast cancer pathogenesis and progression, and is closely linked with resistance to endocrine therapy in advanced breast cancer.
The Breast Cancer Expert Committee of the National Quality Control Center for Cancer, The Expert Committee on Cancer Prevention and Treatment of the Health China Research Center, The Society of Clinical Research on Oncology Medications of the China Anti‐Cancer Association, The Society of Onco‐Pathology of the China Anti‐Cancer Association   +3 more
wiley   +1 more source